Zhang Han,Wang Honghai,Xu Ronglin.Effects of Shenling-Baizhu Powder combined with modified Guilu-Erxian Decoction on bone metabolism and inflammation response in osteoporosis patients[J].,2021,43(12):1204-1208.[doi:10.3760/cma.j.cn115398-202 10728-00245]
参苓白术散合龟鹿二仙汤加减对原发性骨质疏松症脾肾两虚证患者骨代谢及炎症反应的影响
- Title:
- Effects of Shenling-Baizhu Powder combined with modified Guilu-Erxian Decoction on bone metabolism and inflammation response in osteoporosis patients
- Keywords:
- Osteoporosis; Spleen-kidney deficiency; Shenling-Baizhu Powder ; Guilu-Erxian Decoction; Bone metabolism; Inflammatory response
- 摘要:
- 目的 探讨参苓白术散合龟鹿二仙汤加减对原发性骨质疏松症脾肾两虚证患者骨代谢及炎症反应的影响。方法 将符合入选标准的2018年6月-2019年10月本院82例原发性骨质疏松症脾肾两虚证患者采用随机数字表法分为2组,每组41例。对照组口服碳酸钙D3片与阿仑膦酸钠,观察组在对照组基础上服用参苓白术散合龟鹿二仙汤加减。2组均治疗6个月。分别于治疗前后进行中医症状评分,采用双能X线骨密度分析仪检测腰椎L2~4及股骨颈和桡骨远端1/3处骨密度值,采用电化学发光分析仪检测血清抗酒石酸酸性磷酸酶-5b(TRACP-5b)、Ⅰ型胶原C端肽(CTX-Ⅰ)水平,采用放射免疫法检测骨钙素(BGP)水平,采用全自动生化分析仪检测IL-6、IL-10、TNF-、CRP水平。观察治疗期间的不良反应,评价临床疗效。结果 观察组总有效率为95.1%(39/41)、对照组为78.0%(32/41),2组比较差异有统计学意义(χ2=5.145,P=0.023)。观察组治疗后腰背疼痛、胫膝酸软、肢体倦怠、神疲乏力、头晕耳鸣、夜尿频数、纳少便溏、面色不华评分均低于对照组(t值分别为14.268、10.732、20.720、7.564、9.055、15.975、10.826、6.552,P值均<0.001)。治疗后,观察组腰椎L2~4[(0.89±0.06)g/cm3比(0.81±0.04)g/cm3,t=7.104]、股骨颈[(0.80±0.08)g/cm3比(0.72±0.06)g/cm3,t=5.122]、桡骨远端1/3处[(0.65±0.12)g/cm3比(0.56±0.14)g/cm3,t=3.125]骨密度值高于对照组(P<0.01)。治疗后,观察组血清BGP及IL-10水平高于对照组(t值分别为3.875、3.714,P<0.01),TRACP-5b、CTX-Ⅰ水平及IL-6、TNF-、CRP水平低于对照组(t值分别为3.169、5.849、9.412、4.606、5.430,P值均<0.01)。结论 参苓白术散合龟鹿二仙汤加减可有效改善原发性骨质疏松症脾肾两虚证患者临床症状,增加骨密度,调节骨代谢,减轻炎症反应,提高临床疗效。
- Abstract:
- Objective To explore the effects of Shenling-Baizhu Powder combined with modified Guilu-Erxian Decoction on bone metabolism and inflammation response in osteoporosis patients. Methods A total of 82 patients with osteoporosis of spleen-kidney deficiency, meeting the inclusion criteria in the hospital, were enrolled between June 2018 and October 2019. They were divided into observation group and control group by random number table method, 41 in each group. The control group was treated with oral calcium carbonate D3 tablets and alendronate sodium, while the observation group was treated with Shenling-Baizhu Powder combined with modified Guilu-Erxian Decoction on basis of control group. Both groups were treated for 6 months. Before and after treatment, scores of TCM symptoms were conducted. The bone mineral density (BMD) values of lumbar vertebra L 2-4, femoral neck and distal radius1/3 site were detected by dual-energy X-ray BMD analyzer. The levels of serum tartrate-resistant acid phosphatase 5b (TRACP 5b) and type I C-terminal cross linked peptide (CTX-I) were detected by electrochemiluminescence analyzer. The level of bone gla protein (BGP) was detected by radioimmunoassay. The levels of interleukin 6 (IL-6), interleukin 10 (IL-10), tumor necrosis factor α (TNF-α) and C-reactive protein (CRP) were detected by full-automatic biochemical analyzer. The adverse events during treatment were observed. And clinical curative effect was evaluated. Results The differences in response rate between observation group and control group was statistically significant [95.1% (39/41) vs. 78. 0% (32/41); χ2=5.145, P=0.023]. After treatment, scores of clinical symptoms (pain in back and loin, soreness and weakness of waist and knees, limb fatigue, debilitation, dizziness and tinnitus, frequent nocturia, loose stools, poor complexion) in observation group were significantly lower than those in the control group (t=14.268, 10.732, 20.720, 7.564, 9.055, 15.975, 10.826, 6.552, all Ps<0.001). After treatment, BMD values of lumbar vertebra L2-4 (0.89 ± 0.06 g/cm 3 vs. 0.81 ± 0.04 g/cm 3, t=7.104), femoral neck (0.80 ± 0.08 g/cm3 vs. 0.72 ± 0.06 g/cm 3, t=5.122) and distal radius 1/3 site (0.65 ± 0.12 g/cm3 vs. 0.56 ± 0.14 g/cm 3, t=3.125) in observation group were significantly greater than those in the control group (P<0.01). After treatment, levels of serum BGP and IL-10 in observation group were significantly higher than those in the control group ( t=3.875, 3.714, P<0.01), while levels of TRACP-5b, CTX-I, IL-6, TNF-α and CRP were significantly lower than those in the control group (t=3.169, 5.849, 9.412, 4.606, 5.430, all Ps<0.001). Conclusion Shenling-Baizhu Powder combined with modified Guilu-Erxian Decoction can improve clinical symptoms in patients with primary osteoporosis of spleen-kidney deficiency, increase BMD, regulate bone metabolism, alleviate inflammatory response and improve clinical curative effect.
参考文献/References:
[1].祝晓雨,张伟光,赵志刚. 骨质疏松症国内外药物治疗的研究现状[J]. 中国临床药理学杂志,2020,36(5):588-592. DOI :10.13699/j.cnki.1001-6821.2020.05.030.
[2].Narla RR,Hirano LA,Lo S,et al. Suboptimal osteoporosis evaluation and treatment in older men with and without additional high-risk factors for fractures[J]. J Investig Med, 2019 ,67(4):743-749. DOI:10.1136/jim-2018-000907
[3].李娜,杜丽坤,王冰梅. 原发性骨质疏松症的中医证素辨证法[J]. 中国骨质疏松杂志,2019,25(7):1010-1014. DOI:10. 3969/j.issn.1006-7108.2019.07.026.
[4].明章书,吴小华,王巧,等. 加味龟鹿二仙汤对原发性卵巢功能不全小鼠卵巢miR-190表达的影响[J]. 中华中医药杂志,2019,34(11):5410-5414.
[5].章振林,金小岚,夏维波. 原发性骨质疏松症诊疗指南(2017版)要点解读[J]. 中华骨质疏松和骨矿盐疾病杂志,2017, 10(5):411-412. DOI:10.3969/j.issn.1674-2591.2017.05.001.
[6].郑筱萸. 中药新药临床研究指导原则(试行)[M]. 北京:中国医药科技出版社,2002:67-68.
[7].李绍烁,顾一丹,尹恒,等. 基于网络药理学方法分析“龟板-鹿角”药对活性成分治疗骨质疏松症的分子机制[J]. 中国组织工程研究,2020,24(35):5668-5674. DOI:10.3969/j.issn. 2095-4344.2925.
相似文献/References:
[1]康轶鑫 王道全 卢岩 张晶.益肾补骨推拿法治疗骨质疏松症的实验方法探讨[J].国际中医中药杂志,2011,33(12):1086.[doi:10.3760/cma.j.issn.1673-4246.2011.12.012]
KANG Yi-xin*,WANG Dao-quan,LU Yan,et al.Experimental research of treating osteoporosis with the method of kidney-tonifying and bone-strengthening massage therapy[J].,2011,33(12):1086.[doi:10.3760/cma.j.issn.1673-4246.2011.12.012]
[2]杨芳 郑洪新.从“骨肉不相亲”谈骨质疏松症的形成[J].国际中医中药杂志,2012,34(03):232.[doi:10.3760/cma.j.issn.1673-4246.2012.03.013]
YANG Fang,ZHENG Hong-xin.Approach the formation of osteoporosis by the theory of “disharmony between bone and muscle”[J].,2012,34(12):232.[doi:10.3760/cma.j.issn.1673-4246.2012.03.013]
[3]张永良 沈影超 王强 周波凯 顾云峰.社区-综合医院“治未病”互动管理模式对农村老年人骨质疏松自我康复的影响[J].国际中医中药杂志,2012,34(07):598.[doi:10.3760/cma.j.issn.1673-4246.2012.07.007]
ZHANG Yong-liang,SHEN Ying-chao*,WANG Qiang,et al.Effect of the community-general hospital interactive management mode of preventive treatment on osteoporosis self-rehabilitation of rural elderly residents[J].,2012,34(12):598.[doi:10.3760/cma.j.issn.1673-4246.2012.07.007]
[4]王广伟 黄宏兴 霍力为 付丰平 李泽钿.绝经后骨质疏松症患者脂肪含量与骨密度的相关性研究[J].国际中医中药杂志,2012,34(09):782.[doi:10.3760/cma.j.issn.1673-4246.2012.09.005]
WANG Guang-wei*,HUANG Hong-xing,HUO Li-wei,et al.Study of the correlation between fat content of postmenopausal osteoporosis patients and bone mineral density[J].,2012,34(12):782.[doi:10.3760/cma.j.issn.1673-4246.2012.09.005]
[5]康轶鑫 张广元 于有建.单味解表药治疗骨质疏松症的研究进展[J].国际中医中药杂志,2010,32(02):180.[doi:10.3760/cma.j.issn.1673-4246.2010.02.047]
KANG Yi-xin,ZHANG Guang-yuan,YU You-jian..Research progress of single Chinese exterior-relieving medicine in the treatment of osteoporosis[J].,2010,32(12):180.[doi:10.3760/cma.j.issn.1673-4246.2010.02.047]
[6]郑在根 郑洪新.韩国治疗骨质疏松症中药研究概况[J].国际中医中药杂志,2014,36(02):97.[doi:10.3760/cma.j.issn.1673-4246.2014.02.001]
Jung Jaekeun,Zheng Hongxin*.The situation of osteoporosis herbal medicines studies in South Korean journals[J].,2014,36(12):97.[doi:10.3760/cma.j.issn.1673-4246.2014.02.001]
[7]黄桂忠 李伟居 刘意兰.加味海七丸治疗老年性骨质疏松症临床研究[J].国际中医中药杂志,2014,36(06):513.[doi:10.3760/cma.j.issn.1673-4246.2014.06.010]
Huang Guizhong,Li Weiju,Liu Yilan..Curative effect of Jiawei-Haiqi pill on senile osteoporosis[J].,2014,36(12):513.[doi:10.3760/cma.j.issn.1673-4246.2014.06.010]
[8]宋清扬 王小星 牛秀茹 李敏 王爽 孙佳.自拟健脾益肾方治疗老年骨骼肌减少症脾肾两虚、寒湿内蕴证临床研究[J].国际中医中药杂志,2020,42(08):733.[doi:10.3760/cma.j.cn115398-20191009-00033]
Song Qingyang,Wang Xiaoxing,Niu Xiuru,et al.Clinical research of Jianpi-Yishen Decoction in treating sarcopenia aged patients with syndrome of spleen-kidney deficiency and cold-dampness[J].,2020,42(12):733.[doi:10.3760/cma.j.cn115398-20191009-00033]
备注/Memo
(收稿日期:2021-07-28)
更新日期/Last Update:
2021-12-16